Crystallized phenol application

ApprovedSmall molecule

Crystallized phenol application is one of 7 small molecule programs targeting Pilonidal sinus. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pilonidal SinusActive, not recruiting

Pilonidal SinusApproved

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Pilonidal Sinus

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Approved

—2

Silver Nitrate

MMansoura University Hospital

Approved

1 3

Phenol

NNorthwestern University

Approved

1 4

Crystallized phenol application

GGulhane Training and Research Hospital

Approved

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Platelet Rich Plasma

ZZagazig University

Preclinical

1 7

Crystallized Phenol

SSehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pilonidal sinus1 trial

Crystallized Phenol Treatment in Pilonidal Sinus

Completed·GGulhane Training and Research Hospital·Phase 4·NCT04681443·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Crystallized phenol application. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Crystallized phenol application compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Crystallized phenol application. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gulhane Training and Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGulhane Training and Research Hospital

Crystallized phenol application

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pilonidal sinus1 trial

References

Drug Info

Quick Facts

Related News